NIH Ends Clinical Trial of Eli Lily's Coronavirus Antibody Therapy Candidate

A phase 3 clinical trial of a potential COVID-19 antibody therapy developed by Eli Lilly (NYSE: LLY) has been halted permanently, the company reported Monday night. No additional eligible participants will be dosed with LY-CoV555, also known as bamlanivimab. LY-CoV555 was being tested in combination with Gilead Sciences' recently FDA-approved remdesivir antiviral drug to treat the disease.

The stop was ordered by the government's National Institutes of Health (NIH) on the recommendation of an independent advisory committee. The NIH had been sponsoring the study.

The decision followed a temporary halt to the trial mandated by the NIH on Oct. 13 after a participant in the study experienced an adverse event.

Continue reading

Source Fool.com